ATE215373T1 - 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss - Google Patents

21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss

Info

Publication number
ATE215373T1
ATE215373T1 AT98956833T AT98956833T ATE215373T1 AT E215373 T1 ATE215373 T1 AT E215373T1 AT 98956833 T AT98956833 T AT 98956833T AT 98956833 T AT98956833 T AT 98956833T AT E215373 T1 ATE215373 T1 AT E215373T1
Authority
AT
Austria
Prior art keywords
oxidoprogesterone
hydro
treatment
medicinal product
glucocorticoid excess
Prior art date
Application number
AT98956833T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Pedro Lantos
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE215373T1 publication Critical patent/ATE215373T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98956833T 1997-09-23 1998-09-22 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss ATE215373T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (de) 1997-09-23 1997-09-23 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
PCT/EP1998/006021 WO1999015181A1 (en) 1997-09-23 1998-09-22 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids

Publications (1)

Publication Number Publication Date
ATE215373T1 true ATE215373T1 (de) 2002-04-15

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956833T ATE215373T1 (de) 1997-09-23 1998-09-22 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss

Country Status (13)

Country Link
US (1) US6303591B1 (de)
EP (2) EP0903146A1 (de)
AR (1) AR023008A1 (de)
AT (1) ATE215373T1 (de)
AU (1) AU738522B2 (de)
CA (1) CA2303817C (de)
DE (1) DE69804659T2 (de)
DK (1) DK1033990T3 (de)
ES (1) ES2172937T3 (de)
IL (1) IL135232A (de)
PT (1) PT1033990E (de)
WO (1) WO1999015181A1 (de)
ZA (1) ZA988674B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011018A (es) 1999-04-30 2002-05-06 Pfizer Prod Inc Moduladores del receptor glucocorticoide.
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
SI1330468T1 (sl) * 2000-09-18 2007-10-31 Serono Lab Ĺ˝veplovi analogi 21-hidroksi-6,19-oksido-progesterona (21oh-6op) za zdravljenje preseĺ˝ka glukokortikoidov
SI1325022T1 (sl) * 2000-09-18 2007-04-30 Applied Research Systems Metoda za pripravo 21-hidroksi-6,19-oksidoprogesterona (21oh-6op)
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (de) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmazeutische Kombinationen mit einem Aldosteron Synthasehemmer und Glucocorticoid Rezeptorantagonisten oder Cortisol Synthasehemmer oder Corticotropin Releasing Faktor Antagonisten
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
EP2576582B1 (de) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Behandlung von muskeldystrophie
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CN107530435A (zh) 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CA3125151A1 (en) * 2018-12-28 2020-07-02 Panda Consulting Llc Short-acting selective glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen

Also Published As

Publication number Publication date
AU738522B2 (en) 2001-09-20
WO1999015181A1 (en) 1999-04-01
EP1033990B1 (de) 2002-04-03
AR023008A1 (es) 2002-09-04
IL135232A (en) 2005-05-17
IL135232A0 (en) 2001-05-20
AU1334199A (en) 1999-04-12
EP0903146A1 (de) 1999-03-24
CA2303817A1 (en) 1999-04-01
EP1033990A1 (de) 2000-09-13
US6303591B1 (en) 2001-10-16
DE69804659T2 (de) 2002-10-02
DE69804659D1 (de) 2002-05-08
ES2172937T3 (es) 2002-10-01
CA2303817C (en) 2008-04-01
ZA988674B (en) 1999-06-28
DK1033990T3 (da) 2002-07-08
PT1033990E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
ATE432940T1 (de) Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
ATE232543T1 (de) 11beta-halogen-7alpha-substituierte-estratriene verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha- substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE260652T1 (de) Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE69600048D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE69623992D1 (de) Derivate von dolestatin, deren herstellung und verwendung
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE217633T1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
ATE316529T1 (de) Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns)
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee